Evidence map›Paper›PMID 33116396›Full record

ReviewClinical ophthalmology (Auckland, N.Z.)2020

Patient and Economic Burden of Presbyopia: A Systematic Literature Review.

John Berdahl, Chandra Bala, Mukesh Dhariwal, Jessie Lemp-Hull, Divyesh Thakker, Shantanu Jawla

Open access · goldAbstract readReview
In one paragraph

Review in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Design of Progressive Addition Lens for Presbyopia: A Systematic Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Pooled it
  2. Pooled it
  3. Defocus Curve of Emerging Presbyopic Patients.Clinical ophthalmology (Auckland, N.Z.) · 2023
    Trial
  4. Article
  5. Presbyopia: Current Perspectives and Prospects for Patients.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

John BerdahlVance Thompson Vision, Sioux Falls, SD, USA.ORCID 0000-0002-5468-7405
Chandra BalaFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.ORCID 0000-0001-5816-7899
Mukesh DhariwalGlobal Health Economics & Outcomes Research, Alcon Vision LLC, Fort Worth, TX, USA.ORCID 0000-0001-8429-8462
Jessie Lemp-HullClinical Development and Medical Affairs, Alcon Vision LLC, Fort Worth, TX, USA.
Divyesh ThakkerPatient Access Services, Novartis Healthcare Pvt Ltd., Hyderabad, Telangana, India.ORCID 0000-0002-3396-3415
Shantanu JawlaPatient Access Services, Novartis Healthcare Pvt Ltd., Hyderabad, Telangana, India.ORCID 0000-0002-9683-6931
Alcon (United States) · USNovartis (India) · INMacquarie University · AUVance Thompson Vision · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of this systematic literature review (SLR) was to collate, report, and critique published evidence related to epidemiology and patient and economic burden of presbyopia. PATIENTS AND

methodsA systematic literature search was conducted in MEDLINE

resultsInitial systematic literature search yielded 2,228 citations, of which 55 met the inclusion criteria (epidemiology, 44; patient burden, 14; economic burden, 1) and were included in this review. Globally, 1.09 billion people are estimated to be affected by presbyopia. The reported presbyopia prevalence varied across regions and by age groups, with the highest prevalence of 90% reported in the Latin America region in adults ≥35 years. Presbyopic patients report up to 22% decrease in quality-of-life (QoL) score, and up to 80% patients with uncorrected presbyopia report difficulty in performing near-vision related tasks. About 12% of presbyopes required help in performing routine activities, and these visual limitations reportedly induce distress and low self-esteem in presbyopia patients. Uncorrected presbyopia led to a 2-fold increased difficulty in near-vision-related tasks and a >8-fold increased difficulty in very demanding near-vision-related tasks. Further, uncorrected presbyopia leads to a decrement in patients' QoL, evident by the low utility values reported in the literature. Annual global productivity losses due to uncorrected and under-corrected presbyopia in working-age population (<50 years) were estimated at US$ 11 billion (0.016% of the global domestic product (GDP) in 2011, which increased to US$ 25.4 billion if all people aged <65 years were assumed to be productive.

conclusionUncorrected presbyopia affects patients' vision-related quality of life due to difficulty in performing near-vision-related tasks. In addition, un-/under-corrected presbyopia could lead to productivity losses in working-age adults.

Indexed as

burden of diseasepatient satisfactionpresbyopiaproductivity lossquality of lifeutilities

Identifiers

PMID33116396
PMCPMC7588278
OpenAlexW3094113503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.